Cargando…
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy
BACKGROUND: A survey was performed in 2008 to evaluate the profiles of patients with chronic hepatitis B cared for by Italian Infectious Diseases Centers (IDCs). This analysis describes: i) factors associated with access to the anti-HBV treatment in a cohort of HIV/HBV co-infected patients cared for...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640959/ https://www.ncbi.nlm.nih.gov/pubmed/23594964 http://dx.doi.org/10.1186/1756-0500-6-153 |
_version_ | 1782267954683969536 |
---|---|
author | Antonucci, Giorgio Mazzotta, Francesco Angeletti, Claudio Girardi, Enrico Puoti, Massimo De Stefano, Giulio Grossi, Paolo Petrosillo, Nicola Pagano, Gabriella Cassola, Giovanni Orani, Anna Sagnelli, Caterina Armignacco, Orlando Sagnelli, Evangelista |
author_facet | Antonucci, Giorgio Mazzotta, Francesco Angeletti, Claudio Girardi, Enrico Puoti, Massimo De Stefano, Giulio Grossi, Paolo Petrosillo, Nicola Pagano, Gabriella Cassola, Giovanni Orani, Anna Sagnelli, Caterina Armignacco, Orlando Sagnelli, Evangelista |
author_sort | Antonucci, Giorgio |
collection | PubMed |
description | BACKGROUND: A survey was performed in 2008 to evaluate the profiles of patients with chronic hepatitis B cared for by Italian Infectious Diseases Centers (IDCs). This analysis describes: i) factors associated with access to the anti-HBV treatment in a cohort of HIV/HBV co-infected patients cared for in tertiary centers of a developed country with comprehensive coverage under the National Health System (NHS); ii) consistency of current anti-HBV regimens with specific European guidelines in force at the time of the study and factors associated with the receipt of sub-optimal regimens. METHODS: The study focuses on 374 (87.6%) treated patients at some point in their life out of the 427 tested HIV/HBV positive. It is multicentre, cross-sectional in the design. To account for missing values, a Multiple Imputation method is used. RESULTS: Three hundred and thirty-four (89.3%) patients were currently treated. The most common current regimen was combination therapy of tenofovir (TDF) plus LAM/FTC (lamivudine/emtricitabine) (n = 235, 70.4%), as part of antiretroviral treatment. In the multivariate analysis, an increased chance of getting treated was independently associated with increasing years since HBV diagnosis (2–10 years, p <0.001; >10 years, p <0.001). Patients consistently treated with European AIDS Clinical Society (EACS) 2008 guidelines were 255 (76.6%), of whom 202 (79.2%) with an indication to an anti-HIV treatment, 30 (11.8%)without an indication, and 21 (8.2%) with cirrhosis. Among the 78 not-consistent patients, LAM mono-therapy (n = 60, 76.9%) was the most common regimen, 34 (56.7%) of them showing HBV DNA load below 1x10(3) IU/mL. Previous anti-HBV treatment (p = 0.01) and a triple HDV co-infection (p = 0.03) reduced the chance of not-consistent regimens. Conversely, HCV co-infection was independently associated with an increased odds ratio of being inconsistently treated (p = 0.004). CONCLUSION: Our study shows that Italian IDCs treat for HBV infection the vast majority of HIV/HBV co-infected patients with no disparities limiting access to antiviral therapy. In approximately two-thirds of the patients on treatment, anti-HBV regimens are consistent with 2008 EACS guidelines. Finally, our study identifies scenarios in which clinical practice deviates from recommendations, as in case of sub-optimal regimens with effective anti-HBV response. |
format | Online Article Text |
id | pubmed-3640959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36409592013-05-02 Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy Antonucci, Giorgio Mazzotta, Francesco Angeletti, Claudio Girardi, Enrico Puoti, Massimo De Stefano, Giulio Grossi, Paolo Petrosillo, Nicola Pagano, Gabriella Cassola, Giovanni Orani, Anna Sagnelli, Caterina Armignacco, Orlando Sagnelli, Evangelista BMC Res Notes Research Article BACKGROUND: A survey was performed in 2008 to evaluate the profiles of patients with chronic hepatitis B cared for by Italian Infectious Diseases Centers (IDCs). This analysis describes: i) factors associated with access to the anti-HBV treatment in a cohort of HIV/HBV co-infected patients cared for in tertiary centers of a developed country with comprehensive coverage under the National Health System (NHS); ii) consistency of current anti-HBV regimens with specific European guidelines in force at the time of the study and factors associated with the receipt of sub-optimal regimens. METHODS: The study focuses on 374 (87.6%) treated patients at some point in their life out of the 427 tested HIV/HBV positive. It is multicentre, cross-sectional in the design. To account for missing values, a Multiple Imputation method is used. RESULTS: Three hundred and thirty-four (89.3%) patients were currently treated. The most common current regimen was combination therapy of tenofovir (TDF) plus LAM/FTC (lamivudine/emtricitabine) (n = 235, 70.4%), as part of antiretroviral treatment. In the multivariate analysis, an increased chance of getting treated was independently associated with increasing years since HBV diagnosis (2–10 years, p <0.001; >10 years, p <0.001). Patients consistently treated with European AIDS Clinical Society (EACS) 2008 guidelines were 255 (76.6%), of whom 202 (79.2%) with an indication to an anti-HIV treatment, 30 (11.8%)without an indication, and 21 (8.2%) with cirrhosis. Among the 78 not-consistent patients, LAM mono-therapy (n = 60, 76.9%) was the most common regimen, 34 (56.7%) of them showing HBV DNA load below 1x10(3) IU/mL. Previous anti-HBV treatment (p = 0.01) and a triple HDV co-infection (p = 0.03) reduced the chance of not-consistent regimens. Conversely, HCV co-infection was independently associated with an increased odds ratio of being inconsistently treated (p = 0.004). CONCLUSION: Our study shows that Italian IDCs treat for HBV infection the vast majority of HIV/HBV co-infected patients with no disparities limiting access to antiviral therapy. In approximately two-thirds of the patients on treatment, anti-HBV regimens are consistent with 2008 EACS guidelines. Finally, our study identifies scenarios in which clinical practice deviates from recommendations, as in case of sub-optimal regimens with effective anti-HBV response. BioMed Central 2013-04-17 /pmc/articles/PMC3640959/ /pubmed/23594964 http://dx.doi.org/10.1186/1756-0500-6-153 Text en Copyright © 2013 Antonucci et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Antonucci, Giorgio Mazzotta, Francesco Angeletti, Claudio Girardi, Enrico Puoti, Massimo De Stefano, Giulio Grossi, Paolo Petrosillo, Nicola Pagano, Gabriella Cassola, Giovanni Orani, Anna Sagnelli, Caterina Armignacco, Orlando Sagnelli, Evangelista Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title | Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title_full | Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title_fullStr | Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title_full_unstemmed | Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title_short | Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy |
title_sort | access to treatment for hbv infection and its consistency with 2008 european guidelines in a multicentre cross-sectional study of hiv/hbv co-infected patients in italy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640959/ https://www.ncbi.nlm.nih.gov/pubmed/23594964 http://dx.doi.org/10.1186/1756-0500-6-153 |
work_keys_str_mv | AT antonuccigiorgio accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT mazzottafrancesco accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT angeletticlaudio accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT girardienrico accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT puotimassimo accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT destefanogiulio accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT grossipaolo accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT petrosillonicola accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT paganogabriella accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT cassolagiovanni accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT oranianna accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT sagnellicaterina accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT armignaccoorlando accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly AT sagnellievangelista accesstotreatmentforhbvinfectionanditsconsistencywith2008europeanguidelinesinamulticentrecrosssectionalstudyofhivhbvcoinfectedpatientsinitaly |